Development of new antibiotics encouraged with new pharmaceutical payment system

  10 July 2019

The new trial will be led by the National Institute for Health and Care Excellence (NICE) and NHS England and NHS Improvement.

It will test a ‘subscription’ style model that pays pharmaceutical companies upfront for access to drugs based on their usefulness to the NHS.

This will make it more attractive for companies to invest the estimated £1 billion it costs to develop a new drug, as they can be reassured they will still be paid for the drug even though it may be stored for reserves.

Currently, drugs companies are paid by volume of antibiotics sold, while the NHS is trying to reduce their use to prevent antimicrobial resistance (AMR). 

Authors: Department of Health and Social Care
Smart innovation  
Back


Emerging Antimicrobials and Diagnostics in AMR 2019

International Matchmaking Symposium on 19-20 November, 2019 in Amsterdam, The Netherlands.

More information
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!